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A B S T R A C T
In this meta-analysis, we aimed to assess the evidence from neuroimaging studies for chronic alterations in the
brains of MDMA users. The databases PubMed, Embase, and Web of Science were searched for studies published
from inception to August 24, 2018, without any language restriction. Sixteen independent studies comprising
356 MDMA users and 311 controls were included. Of these, ﬁve studies investigated frontal and occipital N-
acetylaspartate/creatine and myo-inositol/creatine ratios, three studies assessed basal ganglia blood ﬂow and
ten studies investigated serotonin transporter (SERT) density in various regions. We found signiﬁcantly de-
creased SERT density in eight of 13 investigated regions. Meta-regression indicated a positive association with
abstinence, but none with lifetime episodes of use. Therefore, other variables (such as doses taken per occasion)
might be more important determinants. Positive associations between time of abstinence and SERT density
might indicate that these alterations are reversible to some extent. Furthermore, there were no signiﬁcant dif-
ferences between user and control groups in terms of neurochemical ratios in the frontal and occipital lobes and
blood ﬂow in the basal ganglia. Overall, MDMA user groups showed heavy use patterns and study quality was
poor.
1. Introduction
MDMA (3,4-methylenedioxymethamphetamine) is an amphetamine
that primarily acts as a serotonin and norepinephrine releasing agent
(Hysek et al., 2012). MDMA is the most common psychoactive com-
ponent found in drugs sold as “ecstasy” (Moreﬁeld et al., 2011) and one
of the most commonly used illicit drugs (UNODC, 2017). Prior to its rise
as a recreational drug in the 1980s, MDMA was used by several psy-
chotherapists as an adjunct in psychotherapy. This approach was
readopted a few years ago, and research has continued on the use of
MDMA in the therapy of posttraumatic stress disorder (Mithoefer et al.,
2018, 2013; Oehen et al., 2013). However, there are concerns that
MDMA might be neurotoxic in humans, especially to serotonergic
neurones (Carvalho et al., 2012). In the last 30 years, numerous studies
investigating this issue have been published. However, studies mostly
focused on heavy users (Szigeti et al., 2018), their results were het-
erogeneous and the debate is still continuing. Despite the large volume
of data, few attempts have been made to meta-analytically summarise
previous ﬁndings. To our knowledge, only one meta-analysis on neu-
roimaging in MDMA users has been published (Roberts et al., 2016).
The authors aggregated ﬁndings on serotonin transporter (SERT) and
serotonin 2 A receptor density in current MDMA users and concluded
that MDMA use was associated with reduced SERT availability in 11 of
14 investigated brain regions. The present meta-analysis extends this
investigation to all neuroimaging modalities and current as well as
previous users, and aims to provide a complete meta-analytical account
of the literature on neuroimaging in human MDMA use. Furthermore,
we examine possible relationships between alterations in SERT density
and lifetime episodes of MDMA consumption using meta-regression. We
also include time of abstinence from MDMA as an explanatory variable
in this model, as several studies have indicated that reductions in SERT
density might be reversible to some extent (Buchert et al., 2006;
McCann et al., 2005; Reneman et al., 2001a; Selvaraj et al., 2009;
Semple et al., 1999; Thomasius et al., 2003).
2. Methods
To ensure quality of reporting throughout the entire process, we
adhered to the recommendation for systematic reviews and meta-ana-
lysis in the PRISMA statement (Moher et al., 2015) and the MOOSE
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guidelines for meta-analyses and systematic reviews of observational
studies (Stroup et al., 2000).
2.1. Search strategy
The data bases PubMed, Embase, and Web of Science Core
Collection were searched to identify studies from inception to August
24, 2018, without any language restriction. The following search term
was used: (mdma OR ecstasy OR 3,4-methylenediox-
ymethamphetamine) AND (mri OR smri OR fmri OR pwi OR dti OR mrs
OR pet OR spect OR imaging OR neuroimaging OR “magnetic re-
sonance imaging” OR “perfusion weighted imaging” OR “diﬀusion
tensor imaging” OR “magnetic resonance spectroscopy” OR “positron
emission tomography” OR “single photon emission computed tomo-
graphy”). Once a study had been rated as eligible from a full text re-
view, its reference list was manually screened for other relevant studies.
2.2. Search strategy and selection criteria
The whole process of study selection and data extraction was con-
ducted by two investigators (FM, RB) independently. In case of dis-
agreement, the reviewers discussed their reasons. If consensus was not
reached, a third investigator (SB) was included.
Firstly, duplicates were removed. Titles and abstracts of all re-
maining records were reviewed and publications which did not meet
inclusion criteria were excluded. The remaining publications were
screened on the basis of a review of the full text. Inclusion criteria were
1) investigation of non-acute eﬀects of MDMA on the human brain, 2)
comparison of an MDMA user group with a control group, 3) applica-
tion of structural, functional or neurochemical neuroimaging techni-
ques (namely magnetic resonance imaging (MRI) - including functional
MRI (fMRI), structural MRI (sMRI), diﬀusion tensor imaging (DWI),
perfusion weighted imaging (PWI) and proton magnetic resonance
spectroscopy (1H-MRS) -, positron emission tomography (PET) and
single photon emission computed tomography (SPECT)), and 4) suﬃ-
cient data for meta-analysis – either reported or received from the au-
thors on request.
Studies which met inclusion criteria were classiﬁed into those ap-
plying whole brain approaches and those applying region of interest
(ROI) approaches. Studies were further classiﬁed into domains (in-
vestigations of SERT density, dopamine transporter density, serotonin
2 A receptor density, glucose metabolism, neurochemical markers,
structural measures, resting state conditions, task-based conditions,
etc.). If necessary, these categories were further divided into sub-
categories, in order to allow direct comparisons (e.g. investigations of
neurochemicals were divided into the respective markers).
In cases of overlapping samples, the study with the largest sample
size was included. If overlaps between studies were suspected but the
original publications did not contain information on that topic, authors
were contacted to request this information. If studies reported long-
itudinal data, the last time point was used.
If the same study reported data on overlapping ROIs, the larger
region was included and the smaller region was discarded (e.g. an ROI
of the frontal cortex was preferred to an ROI of the orbitofrontal
cortex). If a speciﬁed ROI was investigated for the same modality in at
least three independent data sets, meta-analysis was conducted for this
speciﬁc modality. We initially planned to aggregate studies reporting
results on a whole brain level using Seed-based d mapping (Radua and
Mataix-Cols, 2012) if at least ﬁve studies were available for a given
modality. Furthermore, we intended to aggregate associations (reported
as Pearson`s correlation coeﬃcients) between cumulative lifetime doses
and time of abstinence and neuroimaging measures - if at least three
studies were available. However, neither of these analyses was con-
ducted, as there were not enough studies available. Details on excluded
studies are reported in supplementary results.The methods reported
below therefore only apply to meta-analytical procedures for ROI
studies.
2.3. Recorded variables and data extraction
Recorded variables comprised general information (centre where
the study was performed, authors, year of publication, study design,
imaging method, number of subjects, recruitment strategies, and in-
centives for participation) and several demographic variables (age,
gender, cumulative lifetime exposure to ecstasy (tablets, episodes, do-
sage in mg), usual MDMA dose per occasion, maximum MDMA dose per
occasion, age at onset of MDMA use, time since last MDMA use, dura-
tion of MDMA use, and reported matching of control group for use of
other drugs). When data on drug history were missing but could be
computed from the original publication, the missing values were cal-
culated. If necessary, units were transformed.
To calculate eﬀect sizes, means and standard deviations (SD) of the
respective neuroimaging outcome were extracted for MDMA users and
controls. Where these data were not published and were not received on
request, eﬀect sizes were estimated in the following order: estimation of
mean and SD from published ﬁgures (using the software PlotDigitizer;
http://plotdigitizer.sourceforge.net)> estimation based on t values >
estimation based on z values > estimation based on p value. If studies
reported data on drug-naïve and polydrug controls, the latter groups
were preferred. In cases where more than one MDMA user group was
reported, values were treated as independent data sets and the number
of control subjects was adjusted by dividing them by the number of user
groups. If standard errors of the mean (SE) were reported, values were
converted using the formula = ×SD n SE. If ROIs were separately
reported for the right and left hemispheres, values (mean and SD) were
averaged.
2.4. Standardisation of data on lifetime MDMA use
In order to allow comparison of diﬀerent data on lifetime use of
MDMA (total number of ingested tablets, episodes of ecstasy use, total
lifetime use in mg), these values were standardised by estimating the
lifetime episodes of MDMA use for each study. We decided to compare
studies on “episodes of MDMA use” rather than lifetime intake of ec-
stasy tablets because MDMA content of ecstasy tablets varies widely
over time and between diﬀerent countries (Brunt et al., 2012; Cole
et al., 2002; Jalali et al., 2016; Khajeamiri et al., 2011; Mc Fadden et al.,
2006; Schneider and Kovar, 2003; Sherlock et al., 1999; Shetab
Boushehri et al., 2009; Togni et al., 2015). Compared with lifetime
intake of tablets, we expected less variation in terms of “episodes of
use” (i.e. we assume that episodes of use approximately amount to si-
milar quantities of MDMA across diﬀerent countries and periods).
“Episodes of MDMA use” were not reported by eight included studies
(Buchert et al., 2007; Cowan et al., 2007; Daumann et al., 2004; de Win
et al., 2008; Kish et al., 2010; Reneman et al., 2002b, 2001b; Semple
et al., 1999). These missing values were calculated by dividing “cu-
mulative lifetime use in tablets” by “usual dose per episode” reported in
the respective studies. In cases where “usual dose per episode” was not
available, a weighted mean of tablets per episode was calculated across
all included studies, resulting in a value of 3.0 tablets/episode. This
value was higher than a similar estimate (1.3 tablets/episode) recently
reported by our group (Mueller et al., 2015); however, our previous
work focused on moderate MDMA use and a higher value can be ex-
pected in other samples.
2.5. Statistical analysis
Meta-analysis of region of interests was performed using the R
package metafor (version 2.0-0; www.metafor-project.org) and
OpenMEE (www.cebm.brown.edu/openmee) (Wallace et al., 2009).
Because most studies investigated small samples (mean number of
subjects in user groups: 21, mean number of subjects in control groups:
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22), eﬀect sizes were calculated using Hedges’ g, which oﬀers a cor-
rection for small sample sizes. A random eﬀects model (restricted
maximum likelihood estimation) was used to calculate the pooled eﬀect
size, as high heterogeneity was suspected (e.g. due to diﬀerent drug use
patterns) and there was no reason to suspect that the true eﬀect size was
the same across studies. Heterogeneity was assessed using the I2 value.
Additionally, a leave-one-out meta-analysis was conducted. This was
done to assess the robustness of the results by iteratively removing one
study at a time.
2.5.1. Moderator analysis
Potential inﬂuences of the variables “lifetime episodes of MDMA
use” and “time of abstinence from MDMA” on neuroimaging measures
were assessed using meta-regression. This analysis was performed if at
least ten assessments were available for a given domain (Higgins and
Green, 2008). This criterion was met for studies investigating SERT
density. We also initially planned to investigate potential inﬂuences of
the variables “usual dose per episode” and “maximum dose per epi-
sode”, but the included studies did not provide enough data (“usual
dose per episode” was reported for eight assessments and “maximum
dose per episode” was reported for ﬁve assessments only). In order to
account for dependent measurements, multiple outcomes (i.e. results
for diﬀerent ROIs) within the same study were summarised by calcu-
lating combined eﬀect sizes and variances, using procedures described
by Borenstein (Borenstein, 2009). This calculation requires an estimate
of the correlation between brain regions in neuroimaging measures, as
assessed on the basis of previously reported data (see supplement for
more details) (Erritzoe et al., 2010). The resulting eﬀect sizes and
variances (one for each study) were entered as dependent variables in
the meta-regression model. “Lifetime episodes of MDMA use” and “time
of abstinence from MDMA” were entered as explanatory variables.
Meta-regression was calculated using a random eﬀects model (re-
stricted maximum likelihood estimation). Statistical signiﬁcance was
assumed at p < 0.05.
2.5.2. Assessment of publication bias
As the number of studies was small for all investigated domains,
assessment of publication bias using funnel plots might be in-
appropriate (Higgins and Green, 2008). Publication bias was therefore
assessed using Rosenberg’s fail-safe N approach (Rosenberg, 2005). The
fail-safe N indicates the number of unpublished non-signiﬁcant (eﬀect
size of zero) studies that would be required to equalise the statistically
signiﬁcant eﬀect of the studies included in the meta-analysis. Fail-safe
N was calculated for each signiﬁcant outcome; the target signiﬁcance
level was p < 0.05.
2.6. Quality assessment of included studies
The quality of all included studies was assessed with the Quality
Assessment Tool for Observational Cohort and Cross-Sectional Studies
Fig. 1. Flow diagram of the search and selection procedure. The ﬁgure is based on a template provided by PRISMA (www.prisma-statement.org). For details of
studies excluded, with reasons, please see supplementary results.
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of the National Heart, Lung, and Blood Institute of the United States
National Institutes of Health (available from: http://www.nhlbi.nih.
gov/health-topics/study-quality-assessment-tools).
3. Results
934 articles were initially identiﬁed. 78 publications were assessed
on the basis of the full text and 16 studies were included in the quan-
titative synthesis. Overall, this meta-analysis comprises 356 MDMA
users and 311 controls. Meta-analysis was possible for N-acet-
ylaspartate/creatine (NAA/CR) and myo-inositol/creatine (MI/CR) ra-
tios in the frontal and occipital regions - as measured by MRS (ﬁve
studies), CBF of the basal ganglia as measured by MRI/SPECT (three
studies) and SERT density as measured by PET/SPECT in several re-
gions (ten studies reporting 11 assessments). Details of the demo-
graphics of the included studies and on the matching between user and
control groups with regard to use of other drugs are shown in Table 1.
Details of MDMA use patterns are reported in Table 2. Across all stu-
dies, the MDMA user had a mean of 165.5 lifetime episodes of ecstasy
use (median: 193.5, range: 2.0–344.3 episodes).
Mean values and SD of neuroimaging outcomes were received upon
request for one study (Selvaraj et al., 2009) and values were estimated
from ﬁgures for two studies (Erritzoe et al., 2011; McCann et al., 1998).
Three studies reported additional results obtained with diverse meth-
odologies. This required post hoc decisions on the inclusion and ex-
clusion of diﬀerent approaches. A ﬂow diagram of the selection pro-
cedure is given in Fig. 1. Most of the studies assessed on the basis of the
full text review reported heterogeneous assessments which were not
suitable for meta-analysis as based on our criteria described above (see
supplementary results). Reasons for decisions are given in the supple-
mentary results.
3.1. Proton magnetic resonance spectroscopy
Data of ﬁve 1H-MRS studies (Chang et al., 1999; Cowan et al., 2007;
Daumann et al., 2004; de Win et al., 2008; Reneman et al., 2002b) were
included in the analysis of NAA/CR ratios in the occipital lobe (110
users, 120 controls). Across all studies, participants had a mean of
128.5 lifetime episodes of ecstasy use (range: 2.0–344.4 episodes). Four
of the studies also reported NAA/CR ratios in the mid-frontal lobe (97
users, 109 controls) and three reported MI/CR ratios in the same re-
gions (occipital lobe: 97 users, 107 controls; mid-frontal lobe: 88 users,
100 controls). A forest plot of the estimates of eﬀect size is shown in
Fig. 2. In the investigated regions, there were no signiﬁcant diﬀerences
between MDMA users and controls in terms of NAA/CR (occipital lobe:
g=−0.03, CI95%=[−0.29, 0.22], p= 0.79; mid-frontal lobe:
g=−0.22, CI95%=[−0.63, 0.19], p= 0.30) or MI/CR ratios (occipital
lobe: g=−0.03, CI95%=[−0.36, 0.30], p= 0.86; mid-frontal lobe:
g= 0.06, CI95%=[−0.22, 0.34], p= 0.68). Leave-one-out analysis in-
dicated no changes in terms of signiﬁcance for any of the investigated
ratios or regions (see supplementary table 3).
3.2. Cerebral blood ﬂow
Data from CBF studies in two regions of interest - globus pallidus
and putamen – were investigated by two MRI studies (de Win et al.,
2008; Reneman et al., 2001b) and one SPECT study (Chang et al., 2000)
(83 users and 81 controls) and showed no evidence for a signiﬁcant
diﬀerence in CBF between MDMA users and controls in these regions
(globus pallidus: g= 0.14, CI95%=[−0.80, 1.07], p= 0.78; putamen
g=−0.20, CI95%=[−0.51, 0.11], p= 0.20). Participants had a mean
of 92.4 episodes of ecstasy use (range: 2.0–211.0 episodes). Forest plots
are given in Fig. 3. Again, leave-one-out analysis indicated no sig-
niﬁcant changes in results for both regions (see supplementary table 3).
3.3. Serotonin transporter density
We included ten studies which investigated SERT density using PET
(Buchert et al., 2007; Erritzoe et al., 2011; Kish et al., 2010; McCann
et al., 1998, 2005; McCann et al., 2008; Selvaraj et al., 2009; Urban
et al., 2012) and SPECT (de Win et al., 2008; Semple et al., 1999) in a
total of 267 users and 234 controls. Across studies, participants had a
mean of 169.1 lifetime episodes of ecstasy use (range: 2.0–243.8 epi-
sodes). All studies contributed more than one region to the meta-ana-
lysis. One study (Erritzoe et al., 2011) reported a clear outlier for the
amygdala (see supplementary Fig. 1), which was removed from further
analysis. However, exclusion of this study did not signiﬁcantly alter the
results (see supplementary Fig. 1).
Signiﬁcant reductions in SERT density were found in the amygdala
(g=−0.42, CI95%=[−0.78, −0.06], p= 0.02), anterior cingulate
(g=−0.58, CI95%=[−0.99, −0.17], p < 0.01), posterior cingulate
(g=−1.27, CI95%=[−2.10, −0.44], p < 0.01), hippocampus
(g=−0.70, CI95%=[−1.29, −0.11], p= 0.02), occipital lobe
(g=−1.17, CI95%=[−1.69, -0.65], p < 0.01), parietal lobe
(g=−1.12, CI95%=[−1.52, −0.71], p < 0.01), temporal lobe
(g=−1.05, CI95%=[−1.59, −0.50], p < 0.01), and thalamus
(g=−0.32, CI95%=[−0.56, −0.08], p < 0.01). No signiﬁcant al-
terations were observed in caudate (g=−0.11, CI95%=[−0.47, 0.25],
p < 0.55), frontal lobe (g=−0.28, CI95%=[−0.74, 0.19], p < 0.25),
insula (g=−0.41, CI95%=[−1.55, 0.73], p < 0.48), midbrain
(g=−0.26, CI95%=[−0.57, 0.05], p < 0.10), and putamen
(g=−0.18, CI95%=[−0.56, 0.20], p < 0.36). Forest plots are given in
Fig. 4.
SERT density was measured using diﬀerent tracers. Most of the in-
cluded studies applied [11C]DASB (Erritzoe et al., 2011; Kish et al.,
2010; McCann et al., 2005, 2008; Selvaraj et al., 2009; Urban et al.,
2012). Two studies applied the tracer [11C]McN (Buchert et al., 2007;
McCann et al., 1998). [11C]McN and [11C]DASB provide relatively
speciﬁc binding to SERT, while DASB was found to be superior to McN
(Frankle et al., 2004, 2006; Szabo et al., 1995). Two other studies (de
Win et al., 2008; Semple et al., 1999) used the radiotracer [123I]ß-CIT,
which is not speciﬁc to SERT but also binds to the dopamine transporter
(Abi-Dargham et al., 1996; Laruelle et al., 1993). Use of this tracer in
dopamine transporter-rich regions (especially caudate and putamen)
might therefore be misleading. One study used [123I]ß-CIT for the in-
vestigation of caudate and putamen (Semple et al., 1999). However,
removal of this study did not alter the results (see supplementary
Fig. 2). Overall, leave-one-out meta-analysis did not substantially alter
results for most regions in terms of signiﬁcance (see supplementary
table 3). However, removal of some studies resulted in non-signiﬁcant
results for amygdala (McCann et al., 2005, 2008), anterior cingulate
(Kish et al., 2010), and hippocampus (Kish et al., 2010; McCann et al.,
2005, 2008).
3.4. Heterogeneity
Signiﬁcant heterogeneity was found for assessment of CBF in the
globus pallidus: I2= 83.79%, p= 0.02) and for SERT density in several
regions (frontal lobe: I2= 67.3%, hippocampus: I2= 74.32%, insula:
I2= 87.81%, midbrain: I2= 59.37%, occipital lobe: I2= 78.5%, pos-
terior cingulate: I2= 84.5%, putamen: I2= 65.2%, temporal lobe:
I2= 80.01%; all p < 0.05). These values might be interpreted as re-
presenting substantial to considerable heterogeneity (Higgins and
Green, 2008). However, these ﬁndings should be interpreted with
caution, as I2 can be biased when the number of investigated studies is
small (von Hippel, 2015).
3.5. Moderator analysis
Meta-regression indicated no association between the explanatory
variable “lifetime episodes of MDMA use” and aggregated eﬀect sizes
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for SERT density (ß=0.001, Z=0.27, p=0.79). In contrast, a posi-
tive association was found between SERT density and time of ab-
stinence (ß=0.001, Z=2.11, p=0.04). See Fig. 5 for plots of both
meta-regressions. However, most of the studies reported relatively si-
milar times of abstinence and the association for this variable seemed to
be largely driven by a single study (Selvaraj et al., 2009). Indeed, re-
moval of this study considerably altered the result (ß= 0.000,
Z=0.44, p=0.66), which questions the validity of this analysis.
3.6. Publication bias
Rosenberg`s fail-safe N indicated that high numbers of unpublished
non-signiﬁcant studies (eﬀect sizes of zero) would be needed to bring
the p value of the eﬀect to> 0.05 for most of the regions where sig-
niﬁcant alterations in SERT density were found (parietal lobe: 68,
temporal lobe: 72, occipital lobe: 125, anterior cingulate: 28, posterior
cingulate: 114, hippocampus: 41). Fail-safe N was signiﬁcantly lower
for amygdala (12 studies) and thalamus (13 studies). Although there is
no strict criterion, the number of studies seem to be suﬃciently high in
all cases, maybe with the exception of amygdala and thalamus, thus
making it unlikely that the reported results are exclusively due to
publication bias.
3.7. Quality assessment of included studies
The included studies exhibited various sources of bias and were of
poor quality. Common problems were recruitment of user and control
groups from diﬀerent populations (“rave scene” versus general popu-
lation), which could introduce various diﬀerences and potential con-
founding by, for example, use of other illicit drugs. It is striking that, in
all but one study, there were signiﬁcant diﬀerences between control
and user groups in the use of drugs other than MDMA (please see
Table 1 for more details). Other problems were related to issues which
are inherent to these designs, such as unreliable measures of exposure
Fig. 2. Forest plots showing eﬀect size estimates (Hedges’ g) for NAA/CR and MI/CR ratios in occipital and mid-frontal lobe as assessed in magnetic resonance
spectroscopy studies. The size of the data marker is proportional to the weight in the meta-analysis. Error bars represent 95% conﬁdence intervals. There was no
evidence for signiﬁcant diﬀerences between MDMA users and controls in any of the investigated measures. NAA: N-acetylaspartate, CR: creatine, MI: myo-inositol.
Fig. 3. Forest plots showing eﬀect size estimates (Hedges’ g) for cerebral blood ﬂow in the globus pallidus and putamen. The size of the data marker is proportional to
the weight in the meta-analysis. Error bars represent 95% conﬁdence intervals. There was no evidence for signiﬁcant diﬀerences between MDMA users and controls.
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Fig. 4. Forest plots showing eﬀect size estimates (Hedges’ g) for serotonin transporter density (SERT) in all regions of interest included. The size of the data marker is
proportional to the weight in the meta-analysis. Error bars represent 95% conﬁdence intervals. In comparison to controls, SERT density was found to be signiﬁcantly
decreased in MDMA users in the parietal lobe, temporal lobe, occipital lobe, anterior and posterior cingulate, thalamus, and hippocampus.
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to MDMA. Details of the assessment are shown in the supplementary
results.
4. Discussion
This work provides a comprehensive meta-analytical account of the
current evidence from neuroimaging studies in MDMA users. The stu-
dies mostly comprised heavy users with concomitant use of various
other drugs. Compared with controls, these samples exhibit reduced
SERT densities, while no alterations were observed in neurochemical
markers and CBF.
In more detail, SERT density was found to be signiﬁcantly lower in
MDMA users in eight out of 13 investigated regions (namely: parietal,
temporal and occipital lobe, anterior and posterior cingulate, thalamus,
and hippocampus). In contrast, we found no evidence for an association
between MDMA use and alterations in terms of CBF in the basal ganglia
and of NAA/CR and MI/CR ratios in the mid-frontal and occipital lobes.
Especially in the case of CBF, these analyses were limited to a speciﬁc
region, although the basal ganglia exhibit dense serotonergic innerva-
tions (Liu et al., 2011; Miguelez et al., 2014) and might therefore be
particularly vulnerable to MDMA’s neurotoxic eﬀects. Most authors of
the included studies regard SERT density as a measure of the toxic ef-
fects of MDMA (e.g. Semple et al., Urban et al.). Decreases in SERT
density might indeed reﬂect loss of serotonergic neurons caused by
MDMA and this measure has been validated in animals treated with
MDMA (de Win et al., 2004; Reneman et al., 2002a). However, other
reasons are also conceivable, such as MDMA-induced downregulation
of SERT in response to serotonergic stimulation (Biezonski and Meyer,
2010; Kivell et al., 2010). Surprisingly, meta-regression indicated no
relationship between lifetime episodes of MDMA use and reductions in
SERT density. It has been suspected that neurotoxic eﬀects of MDMA
rather depend on doses taken per occasion than on cumulative lifetime
intake (Fox et al., 2001), which could explain the absence of a cumu-
lative dose-response relationship. It would have been interesting to
additionally investigate associations with usual and maximal doses per
occasion. However, this information has only been reported in a few
studies, which renders further investigation impossible. In contrast, a
signiﬁcant association was found between time of abstinence and SERT
density. This ﬁnding might suggest that reductions in SERT are
potentially reversible, as already suspected by several authors (Buchert
et al., 2006; McCann et al., 2005; Reneman et al., 2001a; Selvaraj et al.,
2009; Semple et al., 1999; Thomasius et al., 2003). However, exclusion
of one study had a relative large impact on the result of the meta-re-
gression, so this ﬁnding comes with some uncertainty. Moreover, there
is some evidence for regional diﬀerences in recovery from SERT loss
(Erritzoe et al., 2011; Hatzidimitriou et al., 1999; Scheﬀel et al., 1998),
a possibility which could not be assessed in our analysis. Additionally, if
these ﬁndings were to represent recovery of SERT, it is unclear whether
the system is restored to integrity or to some abnormal state, as in-
dicated by ﬁndings in animals (Fischer et al., 1995), as neuroimaging
measures only provide information on a macro systems level.
We have already pointed out elsewhere (Mueller et al., 2015) that
moderate MDMA use might be a neglected ﬁeld of research as there is
evidence that heavy users are only a minority among MDMA users (von
Sydow et al., 2002). It has been recently estimated that MDMA users in
neuroimaging studies consume approximately seven times more MDMA
per year than the average user and that these subjects correspond to the
top 5–10% of the Global Drug Survey sample (Szigeti et al., 2018).
Therefore, neuroimaging studies might overestimate eﬀects. This is also
reﬂected in the present work. According to a common, but non-em-
pirical, deﬁnition for moderate use (< 50 lifetime episodes or< 100
lifetime tablets), all but one study in this meta-analysis investigated
heavy users and thus might not be representative. This particularly
applies to the signiﬁcance of these studies for investigations on the
therapeutic use of MDMA in posttraumatic stress disorder, where only a
few single doses of MDMA of typically 125mg are administered in a
calm setting (Mithoefer et al., 2018, 2011; Oehen et al., 2013). This
approach mostly involves low cumulative doses of MDMA, e.g. a dose of
375mg was used in the pilot study by Mithoefer et al. (Mithoefer et al.,
2011) and doses between 375 and 525mg per subject were adminis-
tered in a consecutive study (Mithoefer et al., 2018). Only one (de Win
et al., 2008) of the studies included in this meta-analysis investigated a
comparable low cumulative dose. In this study, user reported an
average lifetime dose of six tablets which (given data on MDMA content
of ecstasy tablets in the Netherlands during this period) roughly cor-
responds to doses used by Mithoefer et al. (Brunt et al., 2012). No
signiﬁcant alterations in terms of CBF, MRS, and SERT density were
found in this study.
Fig. 5. Associations between aggregated eﬀect sizes of the studies
investigating SERT density and (A) lifetime episodes of MDMA use
and (B) time of abstinence from MDMA. The size of the data
marker is proportional to the weight in the meta-regression. There
was no signiﬁcant association between lifetime episodes of MDMA
use and reduction in SERT density. In contrast, time of abstinence
was positively associated with SERT density (p < 0.05).
However, exclusion of one study had a relative large impact on the
result of the meta-regression, so this ﬁnding is somewhat un-
certain.
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This meta-analysis has several strengths. Firstly, we provide a
complete meta-analytical account of the current literature. We included
current as well as former users, because we were also interested in
potential recovery of altered neuroimaging measures. Compared with a
previous meta-analysis (Roberts et al., 2016), this resulted in a larger
set of studies and this also allowed assessment of potential moderators
using meta-regression. Moreover, we standardised lifetime MDMA
doses across studies; this increases comparability and is also a pre-
requisite for meta-regression. On the other hand, our analysis is limited
by several factors, including studies with small sample sizes, observa-
tional designs, and various possible confounders between users and
controls, including possible pre-existing psychological or biological
diﬀerences, use of an unknown amount of MDMA, contamination with
other used substances, and life-style related factors. It is striking that
only one of the included studies (Selvaraj et al., 2009) provided a
control group which reportedly exhibited no signiﬁcant diﬀerences in
use of other drugs than MDMA. Therefore, confounding eﬀects by other
drugs than MDMA might be one of the main problems in this ﬁeld. The
included studies exhibit various heterogeneities which complicate
comparisons, e.g. times of abstinence from MDMA vary widely across
studies. Leave-one-out meta-analysis revealed that some results on
SERT density were not robust, which also indicates substantial het-
erogeneity between studies. Our standardisation of lifetime episodes of
MDMA use is only an estimate of the lifetime use of MDMA, as ecstasy
use per episode might vary between countries and over time. Ad-
ditionally, data on episodes of use is likely to be imprecise, as subjects
probably had diﬃculties in remembering all occasions. These un-
certainties might have inﬂuenced the results of the meta-regression
model. Overall, the quality of the included studies was poor. It is evi-
dent that shortcomings in primary studies will be carried over to the
meta-analysis and thus weaken its conclusions. However, the quality
assessment tool used was not speciﬁcally designed for neuroimaging
studies and might comprise criteria which are diﬃcult to meet in re-
search on MDMA. Most of the included studies explicitly aimed to
evaluate (serotonergic) neurotoxicity in MDMA users. For example,
cerebral blood ﬂow is thought to be associated with the vasoactive
properties of serotonin (Chang et al., 2000; de Win et al., 2008;
Reneman et al., 2001b). In the case of MRS, NAA is considered to be a
marker for neurones and MI an indicator for glial cells, while CR serves
as a reference with concentrations assumed to be stable. The included
MRS studies explicitly aimed to evaluate neurotoxic eﬀects of MDMA
(Daumann et al., 2004; de Win et al., 2008; Reneman et al., 2002b).
However, the two techniques do not speciﬁcally assess serotonergic
neurotoxicity and to our knowledge have not been validated for this
purpose.
5. Conclusion
Although MDMA use has been examined by means of neuroimaging
for over 20 years, approaches are very heterogeneous and replications
are rather scarce. Therefore, our analysis is limited by the small number
of studies and restricted to a few regions, especially in the case of CBF.
We found no evidence for alterations in CBF in the basal ganglia and in
neurochemical markers in the occipital and frontal lobes. SERT density
was found to be decreased in several regions. Surprisingly, meta-re-
gression indicated no association between these alterations and lifetime
episodes of MDMA use. Consequently, other factors – such as doses
taken per occasion - might be more important determinants. It is also
possible that reductions in SERT density are related to factors other
than MDMA. For the future, it would be desirable to see studies of
better quality and more attempts to replicate previous ﬁndings in this
area. Particular attention should be paid to potential confounding by
other drugs than MDMA, by e.g., recruitment of controls from the same
population as user groups and more rigorous attempts to statistically
control for these factors. Previous investigations have largely focused
on heavy use patterns and it would be preferable to see more studies in
low to moderate users and in people who have previously used MDMA
but are currently not using it. Further attempts to determine the causes
of reduced SERT density (e.g. neurotoxic eﬀects or transporter down
regulation) would be advantageous.
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